Title : mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer.

Pub. Date : 2011 Oct 19

PMID : 21862729






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Among 59 patients receiving second-line docetaxel, the median overall survival was 25.8 months (95% CI = 9.2 to 42.4 months) for patients with high BRCA1 expression, 19.1 months (95% CI = 3.4 to 34.8 months) for those with intermediate expression, and 9.5 months (95% CI = 8.7 to 10.2 months) for those with low expression (P = .0062). Docetaxel BRCA1 DNA repair associated Homo sapiens